During the past decade, Retina Vitreous Associates Medical Group conducted 59 clinical trials. In the 10-year time frame, 59 clinical trials started and 27 clinical trials were completed, i.e. on average, 45.8% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 15 clinical trials were completed. i.e. 68.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Vitreous Associates Medical Group" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Ionis Pharmaceuticals, Inc." with 5 trials sponsored, "Jaeb Center for Health Research" with 5 trials sponsored, "Neurotech Pharmaceuticals" with 5 trials sponsored and "Allegro Ophthalmics, LLC" with 5 trials sponsored. Other sponsors include 66 different institutions and companies that sponsored additional 60 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Vitreous Associates Medical Group" #1 collaborator was "Genentech, Inc." with 6 trials as a collaborator, "National Eye Institute (NEI)" with 6 trials as a collaborator, "Allergan" with 4 trials as a collaborator, "California Institute for Regenerative Medicine (CIRM)" with 4 trials as a collaborator and "Regeneron Pharmaceuticals" with 3 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Retina Vitreous Associates Medical Group" are "Diabetic Macular Edema" (19 trials), "Macular Degeneration" (12 trials), "Geographic Atrophy" (11 trials), "Diabetic Retinopathy" (6 trials) and "Cytomegalovirus Retinitis" (5 trials). Many other conditions were trialed in "Retina Vitreous Associates Medical Group" in a lesser frequency.

Most popular intervention types in "Retina Vitreous Associates Medical Group" are "Drug" (83 trials), "Other" (12 trials), "Biological" (9 trials), "Procedure" (6 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Sham Procedure" (9 trials), "Ranibizumab" (6 trials), "Fomivirsen sodium" (4 trials) and "Sham" (4 trials). Other intervention names were less common.

The vast majority of trials in "Retina Vitreous Associates Medical Group" are 99 trials for "All" genders.

Currently, there are NaN active trials in "Retina Vitreous Associates Medical Group". undefined are not yet recruiting, 7 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 62 completed trials in Retina Vitreous Associates Medical Group, 1 suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Vitreous Associates Medical Group, 23 "Phase 1" clinical trials were conducted, 45 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".